Transplant Does Not Improve Survival in Follicular Lymphoma Medscape An accompanying editorial notes that HDC–ASCT is "a powerful treatment for patients with follicular lymphoma," and suggests that in the current rituximab era, it should be reserved for salvage treatment. Michael Crump, MD, FRCPC, from Princess Margaret ... |
